Simplify Asset Management Inc. Boosts Holdings in Zevra Therapeutics, Inc. $ZVRA

Simplify Asset Management Inc. raised its holdings in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 137.5% in the 1st quarter, HoldingsChannel.com reports. The fund owned 100,630 shares of the company’s stock after purchasing an additional 58,265 shares during the period. Simplify Asset Management Inc.’s holdings in Zevra Therapeutics were worth $938,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Janney Montgomery Scott LLC lifted its holdings in shares of Zevra Therapeutics by 16.7% in the first quarter. Janney Montgomery Scott LLC now owns 236,834 shares of the company’s stock valued at $2,207,000 after purchasing an additional 33,951 shares in the last quarter. Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new stake in shares of Zevra Therapeutics in the fourth quarter valued at approximately $53,000. DGS Capital Management LLC purchased a new position in shares of Zevra Therapeutics during the 4th quarter worth approximately $133,000. Millennium Management LLC increased its stake in shares of Zevra Therapeutics by 9.6% during the 4th quarter. Millennium Management LLC now owns 1,134,358 shares of the company’s stock worth $10,164,000 after purchasing an additional 99,107 shares in the last quarter. Finally, Man Group plc raised its position in shares of Zevra Therapeutics by 174.4% during the 4th quarter. Man Group plc now owns 92,347 shares of the company’s stock worth $827,000 after purchasing an additional 58,695 shares during the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Stock Performance

ZVRA stock opened at $13.98 on Friday. The company has a 50 day moving average price of $11.68 and a two-hundred day moving average price of $10.00. The stock has a market capitalization of $826.50 million, a P/E ratio of 7.03 and a beta of 0.85. Zevra Therapeutics, Inc. has a one year low of $7.16 and a one year high of $14.58.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.12. The business had revenue of $36.22 million for the quarter, compared to analysts’ expectations of $31.96 million. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%. Research analysts forecast that Zevra Therapeutics, Inc. will post 0.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Wall Street Zen lowered Zevra Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, June 6th. Citizens Jmp raised their price target on Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “market outperform” rating in a research report on Tuesday, June 9th. Maxim Group raised their price target on Zevra Therapeutics from $25.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, June 10th. HC Wainwright reissued a “buy” rating and issued a $26.00 price target on shares of Zevra Therapeutics in a report on Tuesday, June 23rd. Finally, Cantor Fitzgerald upped their price objective on Zevra Therapeutics from $24.00 to $34.00 and gave the company an “overweight” rating in a research report on Monday, June 8th. Nine analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Zevra Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.29.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.